Írsko - angličtina - HPRA (Health Products Regulatory Authority)

mcdermott laboratories ltd., t/a gerard laboratories - valganciclovir - film-coated tablet - 450 milligram(s) - nucleosides and nucleotides excl. reverse transcriptase inhibitors; valganciclovir

Írsko - angličtina - HPRA (Health Products Regulatory Authority)

rowex ltd - valganciclovir hydrochloride - film-coated tablet - 450 milligram(s) - nucleosides and nucleotides excl. reverse transcriptase inhibitors; valganciclovir

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - valganciclovir hydrochloride, quantity: 496.3 mg (equivalent: valganciclovir, qty 450 mg) - tablet, film coated - excipient ingredients: silicon dioxide; stearic acid; crospovidone; croscarmellose sodium; povidone; microcrystalline cellulose; titanium dioxide; hypromellose; polysorbate 80; iron oxide red; macrogol 400 - valganciclovir is indicated for the treatment of cytomegalovirus (cmv) retinitis in adult patients with acquired immunodeficiency syndrome (aids).,valganciclovir is indicated for the prophylaxis of cmv disease in adult and paediatric solid organ transplantation (sot) patients who are at risk.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - valganciclovir hydrochloride, quantity: 496.3 mg (equivalent: valganciclovir, qty 450 mg) - tablet, film coated - excipient ingredients: povidone; silicon dioxide; microcrystalline cellulose; croscarmellose sodium; crospovidone; stearic acid; titanium dioxide; hypromellose; polysorbate 80; iron oxide red; macrogol 400 - valganciclovir is indicated for the treatment of cytomegalovirus (cmv) retinitis in adult patients with acquired immunodeficiency syndrome (aids).,valganciclovir is indicated for the prophylaxis of cmv disease in adult and paediatric solid organ transplantation (sot) patients who are at risk.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - valganciclovir hydrochloride, quantity: 496.3 mg (equivalent: valganciclovir, qty 450 mg) - tablet, film coated - excipient ingredients: stearic acid; microcrystalline cellulose; povidone; croscarmellose sodium; silicon dioxide; crospovidone; titanium dioxide; hypromellose; polysorbate 80; iron oxide red; macrogol 400 - valganciclovir is indicated for the treatment of cytomegalovirus (cmv) retinitis in adult patients with acquired immunodeficiency syndrome (aids).,valganciclovir is indicated for the prophylaxis of cmv disease in adult and paediatric solid organ transplantation (sot) patients who are at risk.

Belgicko - angličtina - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - valganciclovir hydrochloride 496,3 mg - eq. valganciclovir 450 mg - film-coated tablet - 450 mg - valganciclovir hydrochloride 496.3 mg - valganciclovir

Kanada - angličtina - Health Canada

mylan pharmaceuticals ulc - valganciclovir (valganciclovir hydrochloride) - tablet - 450mg - valganciclovir (valganciclovir hydrochloride) 450mg - nucleosides and nucleotides

Kanada - angličtina - Health Canada

mint pharmaceuticals inc - valganciclovir (valganciclovir hydrochloride) - tablet - 450mg - valganciclovir (valganciclovir hydrochloride) 450mg - nucleosides and nucleotides

Spojené štáty - angličtina - NLM (National Library of Medicine)

major pharmaceuticals - valganciclovir hydrochloride (unii: 4p3t9qf9nz) (ganciclovir - unii:p9g3ckz4p5) - treatment of cytomegalovirus (cmv) retinitis: valganciclovir tablets are indicated for the treatment of cmv retinitis in patients with acquired immunodeficiency syndrome (aids) [see clinical studies (14.1)]. prevention of cmv disease: valganciclovir tablets are indicated for the prevention of cmv disease in kidney, heart, and kidney-pancreas transplant patients at high risk (donor cmv seropositive/recipient cmv seronegative [d+/r-]) [see clinical studies (14.1)]. prevention of cmv disease: valganciclovir tablets are indicated for the prevention of cmv disease in kidney transplant patients (4 months to 16 years of age) and heart transplant patients (1 month to 16 years of age) at high risk [see clinical studies (14.2)]. valganciclovir tablets are contraindicated in patients who have had a demonstrated clinically significant hypersensitivity reaction (e.g., anaphylaxis) to valganciclovir, ganciclovir, or any component of the formulation [see adverse reactions (6.1)]. risk summary after oral administr

Spojené štáty - angličtina - NLM (National Library of Medicine)

mckesson corporation dba sky packaging - valganciclovir hydrochloride (unii: 4p3t9qf9nz) (ganciclovir - unii:p9g3ckz4p5) - treatment of cytomegalovirus (cmv) retinitis: valganciclovir tablets are indicated for the treatment of cmv retinitis in patients with acquired immunodeficiency syndrome (aids) [see clinical studies ( 14.1)]. prevention of cmv disease: valganciclovir tablets are indicated for the prevention of cmv disease in kidney, heart, and kidney-pancreas transplant patients at high risk (donor cmv seropositive/recipient cmv seronegative [d+/r-]) [see clinical studies ( 14.1)]. prevention of cmv disease: valganciclovir tablets are indicated for the prevention of cmv disease in kidney transplant patients (4 months to 16 years of age) and heart transplant patients (1 month to 16 years of age) at high risk [see clinical studies ( 14.2)]. valganciclovir tablets are contraindicated in patients who have had a demonstrated clinically significant hypersensitivity reaction (e.g., anaphylaxis) to valganciclovir, gan